Azoulay Salomon 4

4 · MBX Biosciences, Inc. · Filed Feb 3, 2026

AI-generated summary of this filing

Updated Feb 3, 2026

MBX Biosciences CMO Salomon Azoulay Receives 85,000-Share Award

What Happened

Salomon Azoulay, Chief Medical Officer of MBX Biosciences (MBX), received awards on 2026-02-02 totaling 85,000 shares: 15,000 restricted stock units (RSUs) and a 70,000-share derivative award. Both awards were reported as granted at $0.00 (code A on the Form 4).
These are compensation grants (not open-market purchases or sales). The filing shows acquisition via award; no immediate cash proceeds or sales are reported.

Key Details

Transaction date: February 2, 2026; Form 4 filed February 3, 2026 (timely filing).
Price: $0.00 for both awards (standard for equity compensation grants).
Vesting:
- 15,000 RSUs vest in equal quarterly installments over four years (footnote F1).
- 70,000 derivative award vests in 48 equal monthly installments beginning March 2, 2026 (footnote F2).
Shares owned after the transaction: Not specified in the provided filing extract.
Transaction code: A = Award/Grant. No 10b5-1, tax-withholding, or late-filing flags noted in the filing excerpt.

Context

RSUs convert to actual shares as they vest; the derivative award appears to be an option-like award that vests monthly — neither represents an immediate open-market buy or sale.
Because grants are compensation, they don't necessarily signal insider buying interest; their value depends on MBX's future share price at vesting/exercise.

Form 4

Period: 2026-02-02

Chief Medical Officer

Transactions

Award
Common Stock
[F1]
2026-02-02+15,000→ 15,000 total
Award
Stock option (right to buy)
[F2]
2026-02-02+70,000→ 70,000 total
Exercise: $39.07Exp: 2036-02-02→ Common Stock (70,000 underlying)

Footnotes (2)

[F1]Represents the grant of restricted stock units (RSUs). The RSUs will vest over a four (4) year period in equal quarterly installments, subject to the Reporting Person's continued service on such vesting date.
[F2]The shares underlying this option vest and become exercisable in forty eight (48) equal monthly installments, beginning on March 2, 2026, subject to the Reporting Person's continued service on such vesting date.

Signature

/s/ Richard Bartram, attorney-in-fact|2026-02-03

1 file